GlaxoSmithKline plc (GSK) Given a GBX 1,620 Price Target by BNP Paribas Analysts
GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,620 ($20.92) price target by stock analysts at BNP Paribas in a research report issued to clients and investors on Wednesday. The brokerage currently has a “neutral” rating on the stock. BNP Paribas’ price target would suggest a potential upside of 8.43% from the stock’s current price.
A number of other research analysts also recently weighed in on the stock. Jefferies Group LLC reaffirmed a “buy” rating on shares of GlaxoSmithKline plc in a research report on Wednesday. Credit Suisse Group decreased their target price on shares of GlaxoSmithKline plc from GBX 1,775 ($22.92) to GBX 1,725 ($22.28) and set a “neutral” rating for the company in a research report on Wednesday. Liberum Capital reiterated a “buy” rating and issued a GBX 1,900 ($24.54) price target on shares of GlaxoSmithKline plc in a research note on Wednesday, August 30th. Berenberg Bank cut their price target on shares of GlaxoSmithKline plc from GBX 1,885 ($24.34) to GBX 1,835 ($23.70) and set a “buy” rating for the company in a research note on Wednesday, August 9th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.54) price target on shares of GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Tuesday, August 8th. Four research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline plc has a consensus rating of “Hold” and an average price target of GBX 1,714.48 ($22.14).
GlaxoSmithKline plc (LON GSK) traded down 1.09% on Wednesday, reaching GBX 1494.00. 5,910,086 shares of the company’s stock were exchanged. The firm’s market cap is GBX 73.03 billion. The firm’s 50-day moving average is GBX 1,521.96 and its 200-day moving average is GBX 1,615.99. GlaxoSmithKline plc has a 12 month low of GBX 1,446.50 and a 12 month high of GBX 1,745.56.
GlaxoSmithKline plc (LON:GSK) last released its earnings results on Wednesday, July 26th. The company reported $0.52 earnings per share for the quarter, missing analysts’ consensus estimates of $26.23 by $25.71. GlaxoSmithKline plc had a net margin of 16.56% and a return on equity of 295.67%. On average, equities analysts forecast that GlaxoSmithKline plc will post $110.99 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/10/glaxosmithkline-plc-gsk-given-a-gbx-1620-price-target-by-bnp-paribas-analysts.html.
In related news, insider Manvinder Singh Banga purchased 2,267 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were bought at an average cost of GBX 1,599 ($20.65) per share, with a total value of £36,249.33 ($46,815.61). Also, insider Victoria Whyte sold 4,820 shares of GlaxoSmithKline plc stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($21.86), for a total transaction of £81,602.60 ($105,388.87). Over the last three months, insiders acquired 3,144 shares of company stock worth $5,043,015.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.